Scripps Florida scientists discover that angiomotin is required for Yap-mediated tumor growth, challenging earlier findings of its inhibitory role. The study sheds light on a previously unknown pathway regulating cancer progression.
Researchers found that Notch 1 is required for initial tumor growth and survival of cancer cells. Disabling Notch 1 leads to increased cancer cell death through increased p53 stability.
Scientists at Scripps Research Institute have found a way to apply powerful new DNA-editing technology more broadly than ever before. They report their breakthrough in using designer TALE proteins that can target any DNA sequence, enabling precise gene manipulation for biotech and medical applications.
The study showed that the Ebola VP40 protein exists as a dimer and rearranges its structure to assemble filaments for the virus shell or bind RNA, controlling various steps of the life cycle with multiple functions.
A Scripps Research Institute team will study how cellular damage drives the aging process, with a focus on stress caused by DNA damage and potential therapeutic targets for slowing aging. The grant aims to identify ways to minimize degenerative changes associated with aging, potentially leading to improved healthspan.
A Scripps Research Institute study found that overproduction of a specific cluster of microRNAs can trigger lymphomas. The research identified key biological pathways involved in cancer growth and offers new potential therapy targets.
Researchers at Scripps Research Institute found a crucial molecular signal guiding brain development in the neocortex. The discovery may aid research on autism, schizophrenia, and other psychiatric conditions by understanding how molecules like reelin regulate neuron migration.
Scientists at Scripps Research Institute have developed a novel method to increase the potency of RNA treatments, resulting in a 2,500-fold improvement. The breakthrough enables precise targeting of disease-causing RNAs and could lead to more effective therapeutic agents.
Researchers at Scripps Research Institute identified a promising new compound, 6'-guanidinonaltrindole (6'-GNTI), which targets the kappa opioid receptor (KOR) to reduce dopamine release and potential side effects. The study's findings suggest a potential breakthrough in developing effective drugs for addiction with fewer side effects.
Researchers at Scripps Research Institute have successfully synthesized a highly complex, plant-derived compound called ingenol, which has long been of interest for its potential in treating various cancers. The efficient chemical synthesis will enable scientists to investigate the therapeutic properties of ingenol derivatives and pote...
Researchers at Scripps Research Institute have discovered a new type of chemical modification that affects proteins involved in glucose metabolism, potentially playing a role in cancer and diabetes. The modification acts as a regulator of cellular processes, including the production of glucose.
Researchers at Scripps Research Institute discover that parkin enzyme loss leads to reduced levels of protective protein Fbw7β, causing neuronal stress and death. Targeting Fbw7β may offer a new neuroprotective strategy for Parkinson's disease and other neurodegenerative disorders.
Scientists at Scripps Research Institute have determined the 3D structure of the human glucagon receptor, a key drug target for type 2 diabetes. The study's findings provide new information on how cells regulate glucose levels and may aid in the development of treatments for glucose-related disorders.
A new drug candidate, SR9009, has been shown to significantly increase exercise endurance in animal models. The compound works by activating the core biological clock molecule Rev-erbα, which influences lipid and glucose metabolism, fat-storing cell production, and macrophage response during inflammation.
Researchers at The Scripps Research Institute found that MDPV, a stimulant in 'bath salts', can induce strong cravings and repetitive behaviors similar to those seen in methamphetamine users. The study suggests MDPV may be more addictive than methamphetamine, with rats working harder to obtain the drug.
Researchers at TSRI will receive $2 million in funding to investigate the origins of life on Earth, focusing on chirality and replicating systems.
A team of scientists at Scripps Research Institute identified a family of tiny RNA molecules that work as powerful regulators of the immune response in mammals. These RNA molecules enable the differentiation of T cells into follicular helper T cells, which assist B cells in producing antibodies.
Researchers from Scripps Florida Institute have identified small molecules that can control a genetic defect responsible for myotonic dystrophy, a progressive muscle-wasting disease. By activating these compounds, scientists can study the long-term impact of the disease and potentially develop new therapies.
Valery Fokin receives $3.75M grant to establish laboratory at MIPT, focusing on biomarker development for inflammation, cancer, and immune diseases. The lab will facilitate collaborations between Scripps and Russian scientists and companies.
A solitary mutation in the SYNGAP1 gene can destroy critical 'windows' of early brain development, leading to behavioral and intellectual problems. This research sheds light on the early development of neural circuits in the cortex.
Researchers at Scripps Research Institute design a dual inhibitor attacking leucine-rich repeat kinase 2 (LRRK2) and c-jun-N-terminal kinase (JNK) enzymes, two proteins closely linked to Parkinson's disease development. The compound may offer a more effective treatment by eliminating complications of individual inhibitors.
Researchers identified a molecular program controlling neuronal output connection growth via mitochondrial capture. The LKB1-NUAK1 signaling pathway spurs axon branching, pointing to its potential role in developmental brain disorders like autism and schizophrenia.
Researchers at Scripps Research Institute receive $1.4 million from the National Cancer Institute to create a potential new drug targeting malignant cells in CLL, while sparing normal tissues. The study aims to deliver cytotoxic drugs with specific targeting using cell surface receptor TOSO and receptor tyrosine kinase ROR1.
Researchers at Scripps Research Institute found a way for intrinsically disordered proteins to modulate their functionality. They used single-molecule FRET technique to study the dynamics of an adenovirus protein and discovered that it can employ allostery to regulate its interactions with other proteins.
A new anti-tuberculosis compound has shown powerful activity against ordinary active TB bacteria, non-replicating TB bacteria, and extensively drug-resistant strains. The compound works in two different ways, targeting TB replication and dormancy, and shows no toxicity or adverse side effects.
Researchers found that blocking kappa opioid receptors in the central amygdala reduced signs of cocaine addiction in rats, suggesting a potential therapeutic approach. The study highlights an alternative to traditional pleasure-seeking circuits and provides hope for new treatments targeting negative motivational factors.
Scripps Research Institute scientists have identified key triggers of an important cancer-blocking mechanism in cells, known as oncogene-induced senescence. The study reveals a cascading interaction of three enzymes necessary to initiate this response.
Scientists at Scripps Research Institute have identified an extraordinary family of cow antibodies that could lead to breakthroughs in human medicine. The unique structure and mechanism of these antibodies may allow for the creation of new therapeutic proteins.
A team from The Scripps Research Institute has developed a new technique to selectively repress unwanted immune reactions without disabling the immune system as a whole. This method exploits a natural mechanism to target B-cells responsible for Factor VIII rejection, preventing an unwanted immune response in mice for several months.
The Esther B. O'Keeffe Charitable Foundation has donated $250,000 to The Scripps Research Institute to fund neuroscience training programs and public outreach initiatives. This gift will support the training of next-generation neuroscientists and raise community awareness of brain diseases.
The newly reported technique can greatly speed the process of discovering therapeutic antibodies with desired biological effects. The team discovered an antibody that potently mimics thrombopoietin, a hormone essential for blood clotting.
Researchers at Scripps Research Institute discovered how to control natural gene silencing processes, leading to a powerful new class of drugs against viral infections, cancers and diseases. The study found that guide RNAs can be designed to destabilize or stabilize the miRNA-Argonaute complex.
A preclinical study by Scripps Research Institute successfully tested a new vaccine against heroin, which targets the drug and its metabolites, preventing them from reaching the brain. The vaccine effectively blocks relapse in rats with heroin addiction, offering hope for therapy.
Researchers solved the structure of the smoothened receptor, finding it has a similar shape to GPCRs despite low genetic similarity. This discovery provides insight into the role of SMO in cancer and embryonic development, potentially leading to new treatments for skin cancer and other diseases.
Researchers uncovered how an enzyme co-factor bestows specificity on a class of proteins with nonspecific biochemical activity, expanding scientists' view of co-factors role in disease. The discovery suggests manipulating co-factors could alter protein activity, potentially treating diseases.
Researchers from Scripps Research Institute and universities identified nearly 6,000 transcripts from sea slug genome, shedding light on RNA molecules transported to synapses. The new approach offers insights into localized translation and its role in maintaining long-term memories.
Researchers at Scripps Research Institute found an antibody that directly transforms bone marrow stem cells into neural progenitor cells, a type of almost-mature brain cell. This discovery could lead to simpler and safer cell therapies for treating various conditions.
Scientists at Scripps Research Institute discover that type 1 interferon proteins initiate persistent infections and limit antiviral immune responses in mice. Blocking interferon receptors earlier restores antiviral immunity and virus clearance.
Researchers have discovered that brain damage in Alzheimer's disease is caused by the overactivation of an enzyme called AMPK, leading to the loss of synapses and neuron damage. Blocking this enzyme in mouse models prevented further neuronal loss.
Researchers at Scripps Research Institute illuminate the copper-catalyzed azide–alkyne cycloaddition (CuAAC) reaction, revealing key findings on its mechanism. The discovery enables better control, efficiency, and versatility in pharmaceutical synthesis, enabling the development of new reactions.
Scientists have identified two compounds, tacrolimus and astemizole, that show anti-prion activity and promise in treating human prion diseases. Astemizole, an antihistamine, stimulates autophagy, a process involved in protein misfolding neurodegenerative diseases like Alzheimer's and Parkinson's.
A team of scientists developed a new technique for designing vaccine immunogens that can stimulate the immune system to produce antibodies effective against multiple strains of HIV. The approach, using artificial proteins engineered to bind germline B cells, offers hope for better protection against fast-mutating viruses.
Researchers from Scripps Research Institute have received a $10M NIH grant to develop anti-smoking drug candidates. The team aims to create novel compounds that target hypocretin-1 receptors, which play a critical role in maintaining tobacco addiction.
Researchers from Scripps Research Institute have identified a class of compounds that can modify cell signaling activity, including anti-inflammatory effects, which could lead to innovative treatments for breast cancer. The study focuses on compounds interacting with the estrogen receptor-α, a key target in breast cancer treatment.
Researchers have determined the high-resolution atomic structures of two human serotonin receptor types, shedding light on why certain drugs interact with these receptors in complex and sometimes harmful ways. The study's findings offer valuable insights into designing safer and more effective medicines.
Researchers at Scripps Research Institute developed a cutting-edge technology to screen human blood for disease markers. The 'antigen surrogate' method accurately identified biomarkers for neuromyelitis optica, a rare autoimmune disorder, in a recent study published in Chemistry & Biology.
Scripps Research is developing a new diagnostic test for Onchocerciasis, or river blindness, using a biomarker detectable in urine. The test aims to provide accurate and painless diagnosis, guiding treatment decisions and helping global health leaders eradicate the disease.
Scientists at Scripps Research Institute have found a telltale molecular marker for Onchocerciasis in patients' urine, detectable during active infections. The biomarker could form the basis of a non-invasive, portable test with significant advantages over current diagnostic methods.
A new study reveals that pseudogenes can regulate cancer-related genes like PTEN, potentially leading to new treatments. The research found that pseudogenes sharing sequences with PTEN can control its activity in two ways.
Ron Davis, chair of the Neuroscience Department at Scripps Research Institute, has been selected for a prestigious Javits Neuroscience Investigator Award to study active forgetting in memory formation. The grant will focus on understanding the role of dopamine signaling in learning and memory, with potential implications for treating d...